HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Refined testing and targeted therapy lead new fight against prostate cancer. Interview by Wayne Kuznar.

Abstract
Prostate cancer screening and intervention remain controversial, despite significant strides in the detection and treatment of this common malignancy. False-positive results from the test for prostate specific antigen (PSA) lead to unnecessary workups and biopsies, as well as psychological stress for patients. Radial prostatectomy remains the most effective treatment for organ-confined cancer, yet many patients opt for the opt for the organ-sparing advantage of radiation therapy. Others may opt for unproven interventions such as cryoablation. Recently-developed tools designed for use with PSA testing are helping to improve screening accuracy in the lower tier of serum total PSA (2.5 to 10.0 ng/mL).
AuthorsW J Catalona
JournalGeriatrics (Geriatrics) Vol. 54 Issue 9 Pg. 49-54; quiz 57 (Sep 1999) ISSN: 0016-867X [Print] United States
PMID10494227 (Publication Type: Interview)
Chemical References
  • Biomarkers, Tumor
  • Prostate-Specific Antigen
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor
  • Cryosurgery
  • Humans
  • Male
  • Mass Screening (methods)
  • Middle Aged
  • Prostate-Specific Antigen (blood)
  • Prostatectomy
  • Prostatic Neoplasms (therapy)
  • Radiotherapy (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: